CLINICAL TRIALS PROFILE FOR PRIDOPIDINE
✉ Email this page to a colleague
Clinical Trials for Pridopidine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00665223 ↗ | A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease. |
NCT00665223 ↗ | A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease | Completed | Teva Pharmaceutical Industries | Phase 3 | The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease. |
NCT00724048 ↗ | A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2/Phase 3 | The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease. |
NCT00724048 ↗ | A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease | Completed | Teva Pharmaceutical Industries | Phase 2/Phase 3 | The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease. |
NCT01306929 ↗ | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | Completed | Prilenia | Phase 2 | Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment. |
NCT01306929 ↗ | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | Completed | Teva Branded Pharmaceutical Products, R&D Inc. | Phase 2 | Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment. |
NCT02006472 ↗ | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease | Completed | European Huntington's Disease Network | Phase 2 | This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Pridopidine
Condition Name
Clinical Trial Locations for Pridopidine
Trials by Country
Clinical Trial Progress for Pridopidine
Clinical Trial Phase
Clinical Trial Sponsors for Pridopidine
Sponsor Name